Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
31 juil. 2024 07h35 HE
|
ALTERITY THERAPEUTICS LIMITED
Highlights Positive interim data reported from ATH434-202 Phase 2 clinical trial showing improvement on the UMSARS Activities of Daily Living Scale and stable or improved neurological symptoms in...
Alterity Therapeutics to Present at MST Financial Webinar
24 juil. 2024 07h35 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
17 juil. 2024 07h35 HE
|
ALTERITY THERAPEUTICS LIMITED
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
17 juil. 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated...
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
12 juin 2024 19h22 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
29 mai 2024 19h21 HE
|
ALTERITY THERAPEUTICS LIMITED
- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May ...
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
08 mai 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) --...
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
30 avr. 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a primate model of Parkinson’s...
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
29 avr. 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
– New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:...
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
17 avr. 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing...